Sale!

DYSF Gene Limb-Girdle Muscular Dystrophy Autosomal Recessive Type 2B Genetic Test

Original price was: $700.Current price is: $500.

-29%

The DYSF Gene Limb-Girdle Muscular Dystrophy Autosomal Recessive Type 2B NGS Genetic DNA Test is a comprehensive diagnostic tool that identifies mutations in the DYSF gene responsible for this specific form of muscular dystrophy. Using next-generation sequencing technology, this test provides accurate detection of genetic variants that cause progressive muscle weakness and wasting. The test is essential for individuals experiencing unexplained muscle weakness, difficulty walking, or with family history of muscular dystrophy. Early diagnosis enables better disease management, treatment planning, and genetic counseling. Results are typically available within 3-4 weeks from blood or DNA samples. This advanced genetic testing is available for $500 USD, providing crucial insights into neuromuscular health and inheritance patterns.

Trusted Testing. Expert Care. Guaranteed Privacy.

  • Accredited and Trusted
  • Expert Scientists, Advanced Technology
  • Data Privacy Guaranteed
Guaranteed Safe Checkout

DYSF Gene Limb-Girdle Muscular Dystrophy Autosomal Recessive Type 2B NGS Genetic DNA Test

Comprehensive Genetic Testing for Neuromuscular Disorders

The DYSF Gene Limb-Girdle Muscular Dystrophy Autosomal Recessive Type 2B NGS Genetic DNA Test represents a cutting-edge diagnostic approach for identifying specific genetic mutations associated with limb-girdle muscular dystrophy type 2B. This progressive neuromuscular disorder affects the muscles around the hips and shoulders, leading to significant mobility challenges and quality of life impacts. Our advanced genetic testing provides definitive answers for patients and families affected by this condition.

What This Test Measures and Detects

This comprehensive genetic analysis utilizes next-generation sequencing (NGS) technology to examine the entire DYSF gene for pathogenic variants. The test specifically identifies:

  • Point mutations, deletions, and insertions in the DYSF gene
  • Autosomal recessive inheritance patterns
  • Genetic variants responsible for dysferlin protein deficiency
  • Mutations leading to progressive muscle degeneration
  • Carrier status for family members

Who Should Consider This Genetic Test

Clinical Indications and Symptoms

This test is recommended for individuals experiencing:

  • Progressive muscle weakness in hips, thighs, and shoulders
  • Difficulty climbing stairs or rising from seated positions
  • Frequent falls or balance problems
  • Muscle wasting in limb-girdle regions
  • Elevated creatine kinase levels without clear cause
  • Family history of muscular dystrophy or unexplained muscle weakness
  • Onset of symptoms typically in late adolescence or early adulthood

Key Benefits of Genetic Testing

Undergoing DYSF gene testing provides numerous advantages for patients and their families:

  • Accurate Diagnosis: Confirms or rules out limb-girdle muscular dystrophy type 2B
  • Treatment Planning: Enables targeted management strategies and interventions
  • Genetic Counseling: Provides essential information for family planning decisions
  • Early Intervention: Allows for proactive management of symptoms
  • Carrier Detection: Identifies asymptomatic carriers within families
  • Research Contribution: Advances understanding of neuromuscular disorders

Understanding Your Test Results

Interpreting Genetic Findings

Your test results will fall into one of several categories, each with specific implications:

  • Positive Result: Identifies pathogenic mutations in both DYSF gene copies, confirming diagnosis of limb-girdle muscular dystrophy type 2B
  • Carrier Status: Detection of a single mutated copy indicates carrier status without disease manifestation
  • Negative Result: No pathogenic variants detected, suggesting alternative diagnoses should be considered
  • Variant of Uncertain Significance: Identifies genetic changes with unknown clinical impact requiring further evaluation

Clinical Implications and Next Steps

Following testing, our genetic counselors and neurologists will provide comprehensive guidance on:

  • Disease management strategies and symptom treatment
  • Physical therapy and rehabilitation recommendations
  • Family member testing options
  • Reproductive planning considerations
  • Long-term monitoring and care coordination

Test Information and Pricing

Test Component Details
Test Name DYSF Gene Limb-Girdle Muscular Dystrophy Autosomal Recessive Type 2B NGS Genetic DNA Test
Regular Price $700 USD
Discount Price $500 USD
Turnaround Time 3 to 4 Weeks
Sample Type Blood, Extracted DNA, or One Drop Blood on FTA Card
Testing Method Next-Generation Sequencing (NGS) Technology

Pre-Test Requirements and Preparation

To ensure accurate testing and comprehensive care, we require:

  • Complete clinical history of the patient
  • Genetic counseling session to create detailed family pedigree
  • Documentation of symptoms and progression timeline
  • Previous diagnostic test results if available

Nationwide Testing Availability

We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our network of certified genetic testing facilities ensures consistent, high-quality results regardless of location.

Take Control of Your Neuromuscular Health

Don’t let uncertainty about muscle weakness and mobility issues affect your quality of life. Our DYSF gene testing provides the clarity needed for proper diagnosis and management of limb-girdle muscular dystrophy type 2B. With our discounted price of $500 USD and comprehensive genetic counseling support, you can make informed decisions about your health and future.

Ready to schedule your genetic test? Contact our genetic specialists today at +1(267) 388-9828 or book your appointment online. Take the first step toward understanding your genetic health and planning for the future.